The Medicines and Healthcare products Regulatory Agency (MHRA) has published new guidance on medical devices to help stakeholders prepare for the end of the transition period.
Further new and updated guidance may be issued depending on the precise terms upon which the UK leaves the EU, so stakeholders are advised to monitor these pages for updates. The MHRA has published the following guidance to help stakeholders prepare for the end of the transition period:
- Medical devices:
The guidance covers a range of related matters, including how medical devices which are regulated in the UK will change after the transition period has ended. Both the UK and EU are keeping their Brexit-related guidance under review and re-issuing stakeholder notices where necessary or appropriate to aid preparation for the end of transition. Not all changes or updates are substantive. For instance, in some cases, the detail of the guidance may not have changed, but the context, timescales or status of the arrangements outlined may have been updated. In other cases, guidance may contain placeholders for more detail (pending implementation of relevant legislation, regulatory changes, fees or systems).
The guidance will be updated as those arrangements are finalised during transition. As revised Brexit notices and guidance documents are being issued it is a good idea to bookmark the relevant guidance pages and check for updates, in particular:
The bulk of the government’s Brexit guidance has been gathered in its revised webpage: GOV.UK—Transition